News | May 02, 2026
Merck posts mixed Q1 2026 results as blockbuster drugs drive growth
But acquisition charges drag earnings into loss
But acquisition charges drag earnings into loss
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
Subscribe To Our Newsletter & Stay Updated
